Compare · CPNG vs LOGC
CPNG vs LOGC
Side-by-side comparison of Coupang Inc. (CPNG) and ContextLogic Inc. (LOGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CPNG and LOGC operate in Catalog/Specialty Distribution (Consumer Discretionary), so they compete in similar markets.
- CPNG is the larger of the two at $27.20B, about 557.6x LOGC ($48.8M).
- Over the past year, CPNG is down 45.6% and LOGC is up 0.0% - LOGC leads by 45.6 points.
- LOGC has been more active in the news (9 items in the past 4 weeks vs 3 for CPNG).
- CPNG has more recent analyst coverage (25 ratings vs 5 for LOGC).
- Company
- Coupang Inc.
- ContextLogic Inc.
- Price
- $15.45+1.98%
- $7.05+1.00%
- Market cap
- $27.20B
- $48.8M
- 1M return
- -10.14%
- +0.00%
- 1Y return
- -45.64%
- +0.00%
- Industry
- Catalog/Specialty Distribution
- Catalog/Specialty Distribution
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 3
- 9
- Recent ratings
- 25
- 5
Coupang Inc.
Coupang, Inc. owns and operates in e-commerce business through its mobile applications and Internet websites primarily in South Korea. It sells various products and services in the categories of home goods and décor products, apparel, beauty products, fresh food and groceries, sporting goods, electronics, and everyday consumables, as well as travel, and restaurant order and delivery services. The company was founded in 2010 and is based in Seoul, South Korea.
ContextLogic Inc.
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Latest CPNG
- Coupang Jumps to No. 132 on Fortune 500® as the Company Scales AI-Driven Global Commerce
- SEC Form 144 filed by Coupang Inc.
- SEC Form DEFA14A filed by Coupang Inc.
- SEC Form 144 filed by Coupang Inc.
- Director Toubassy Ambereen was granted 69 shares, increasing direct ownership by 0.14% to 50,382 units (SEC Form 4)
- Amendment: Coupang Inc. filed SEC Form 8-K: Leadership Update
- WV-Based Family Business Expands Globally with Coupang
- Amendment: SEC Form SCHEDULE 13G/A filed by Coupang Inc.
- Coupang downgraded by Deutsche Bank with a new price target
- Coupang downgraded by Citigroup with a new price target
Latest LOGC
- Director Levy Paul S bought $899,618 worth of shares (99,428 units at $9.05) (SEC Form 4)
- Director Levy Paul S bought $232,344 worth of shares (25,693 units at $9.04) (SEC Form 4)
- SEC Form 4 filed by CFO & COO Stewart Scott Matthew
- SEC Form 3 filed by new insider Stewart Scott Matthew
- ContextLogic Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- ContextLogic Holdings Inc. Announces Scott Stewart as Chief Financial Officer & Chief Operating Officer
- Director Bobbili Raja bought $1,134,825 worth of shares (130,201 units at $8.72) (SEC Form 4)
- ContextLogic Holdings Inc. Publishes Q&A Following First Quarter 2026 Results
- Director Bobbili Raja bought $1,310,960 worth of shares (150,000 units at $8.74) (SEC Form 4)
- SEC Form 10-Q filed by ContextLogic Inc.